enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.860
-0.060 (-3.12%)
Jul 8, 2026, 4:00 PM EDT - Market closed
enGene Therapeutics Employees
As of October 31, 2025, enGene Therapeutics had 82 total employees, including 81 full-time and 1 part-time employees. The number of employees increased by 25 or 43.86% compared to the previous year.
Employees
82
Change (1Y)
25
Growth (1Y)
43.86%
Revenue / Employee
n/a
Profits / Employee
-$1,546,951
Market Cap
124.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 82 | 25 | 43.86% | 81 | 1 |
| Oct 31, 2024 | 57 | 24 | 72.73% | 56 | 1 |
| Oct 31, 2023 | 33 | - | - | 31 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| PepGen | 59 |
| Aardvark Therapeutics | 40 |
| Enlivex | 34 |
| Cue Biopharma | 29 |
| Genelux | 26 |
| Spero Therapeutics | 25 |
| ProMIS Neurosciences | 11 |
ENGN News
- 20 days ago - enGene downgraded to Underweight from Equal Weight at Morgan Stanley - TheFly
- 22 days ago - enGene price target lowered to $4 from $6 at H.C. Wainwright - TheFly
- 23 days ago - enGene implements plan to reduce workforce by 50% - TheFly
- 23 days ago - enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 23 days ago - enGene Therapeutics Earnings release: Q2 2026 - Filings
- 23 days ago - enGene Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - enGene Therapeutics Transcript: AGM 2026 - Transcripts
- 7 weeks ago - enGene price target lowered to $2 from $9 at UBS - TheFly